Identification of Potential Therapeutic Targets in the Liver of Pioglitazone-Treated Type 2 Diabetes Sprague-Dawley Rats via Expression Profile Chip and iTRAQ Assay

Figure 5

GO analysis of differentially expressed proteins after treatment with pioglitazone. iTRAQ assay results of the DM model group and the pioglitazone-treated group.